Products are region specific and may not be approved in some countries/regions.
Please contact SDI at info@spectraldx.com to obtain appropriate product information for your country of residence. This product is currently undergoing clinical investigation in United States.

Toraymyxin is a Polymyxin B extracorporeal direct hemoperfusion adsorption column which is highly effective in removing endotoxin in the bloodstream. Toraymyxin has been approved and marketed by Toray Industries in Europe and Japan since 2002 and 1994 respectively, and has been used safely on more than 100,000 patients. Spectral holds the exclusive rights for Toraymyxin in the U.S. and Canada, and is currently conducting a Phase III clinical trial for severe sepsis and septic shock. Toraymyxin has the potential to meet the needs of the more than 250,000 U.S. patients diagnosed with severe sepsis and septic shock each year.

Were there previous Toraymyxin trials and what were the results?

Toraymyxin has been used in more than 100,000 patients in markets outside of the U.S. and has been tested in more than 90 published studies.

The most recent results of a randomized controlled trial (the EUPHAS - Early use of polymyxin B hemoperfusion in abdominal sepsis (surgery) trial) were published in the Journal of the American Medical Association (JAMA. 2009; Vol. 301 No. 23, 2445-2452) . The results demonstrated that Toraymyxin adsorbs endotoxin from the bloodstream, and when added to conventional therapy, significantly improved hemodynamics and organ function. Toraymyxin reduced 28-day mortality in patients with severe sepsis and septic shock in comparison to those patients in the conventional therapy group.

Toraymyxin

 

 

135-2 The West Mall  •  Toronto, Ontario  •  M9C 1C2  Canada

Tel: 416.626.3233  •  Toll Free: 1.888.426.4264  •  Fax: 1.416.626.7383

info@spectraldx.com